NASDAQ:BRKR - Bruker Stock Price, News, Headlines & Rumors

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker declared a quarterly dividend on Monday, August 13th. Shareholders of record on Tuesday, September 4th will be given a dividend of $0.04 per share on Friday, September 21st. This represents a $0.16 annualized dividend and a yield of 0.47%. The ex-dividend date is Friday, August 31st. View Bruker's Dividend History.

Bruker announced that its board has approved a share repurchase plan on Sunday, June 4th 2017, which allows the company to buyback $225,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its shares are undervalued.

Bruker Co. (NASDAQ:BRKR) announced its quarterly earnings data on Thursday, August, 2nd. The medical research company reported $0.25 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.25. The medical research company had revenue of $443.70 million for the quarter, compared to analysts' expectations of $436.10 million. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The firm's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 EPS. View Bruker's Earnings History.

Bruker is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Bruker.

Bruker issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share guidance of $1.34-1.38 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of approx $1.88 billion, compared to the consensus revenue estimate of $1.88 billion.

9 equities research analysts have issued twelve-month target prices for Bruker's shares. Their predictions range from $24.00 to $42.00. On average, they expect Bruker's share price to reach $33.1111 in the next year. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Bruker.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bruker.

Some companies that are related to Bruker include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class B (BIO.B), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT) and HTG Molecular Diagnostics (HTGM).

News stories about BRKR stock have trended positive this week, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bruker earned a news impact score of 0.32 on Accern's scale. They also gave news stories about the medical research company an impact score of 47.40 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Bruker.

Bruker's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (4.76%), BlackRock Inc. (3.43%), Acadian Asset Management LLC (3.02%), Millennium Management LLC (0.82%), Epoch Investment Partners Inc. (0.72%) and Dimensional Fund Advisors LP (0.62%). Company insiders that own Bruker stock include Frank H Laukien, Ingen Chris Van, Mark Munch and Richard Kniss. View Institutional Ownership Trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Acadian Asset Management LLC, First Trust Advisors LP, Sensato Investors LLC, Janus Henderson Group PLC, First Quadrant L P CA, Eagle Asset Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Bruker.

BRKR stock was bought by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Citadel Advisors LLC, Fuller & Thaler Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P., Millennium Management LLC, CWM LLC and MUFG Securities EMEA plc. View Insider Buying and Selling for Bruker.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BRKR stock can currently be purchased for approximately $33.98.

Bruker has a market capitalization of $5.30 billion and generates $1.77 billion in revenue each year. The medical research company earns $78.60 million in net income (profit) each year or $1.21 on an earnings per share basis. Bruker employs 6,200 workers across the globe.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at 978-663-3660 or via email at [email protected]